R. Mahlberg

发表

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2019, The Lancet.

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.

W. Brugger, G. Romieu, P. Fargeot, 2007, Critical reviews in oncology/hematology.

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin

V. Heinemann, P. Pfeiffer, M. Möhler, 2016, Chemotherapy.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

R. Greil, H. Eich, R. Semrau, 2015, The Lancet.

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice

P. Schirmacher, M. Egger, J. Trojan, 2016, The Lancet. Oncology.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

C. Rübe, M. Ziepert, N. Schmitz, 2014, Blood.

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

M. Ebert, W. Bechstein, P. Reichardt, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

G. Ehninger, M. Schaich, T. Illmer, 2006, Leukemia.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

C. Denkert, F. Marmé, S. Loibl, 2022, Breast.

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer

V. Heinemann, A. Wein, A. Hochhaus, 2005 .

1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma

W. Bechstein, P. Reichardt, R. Hofheinz, 2020 .

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.

M. Ebert, W. Bechstein, P. Reichardt, 2020 .

(Ph+ ALL) outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2013 .

ALL) + (Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2009 .

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.

M. Stauch, Y. Ko, F. Lordick, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Antimicrobial therapy of unexplained fever in neutropenic patients

O. Sezer, K. Höffken, W. Kern, 2003, Annals of Hematology.

Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG—German Cancer Society)

O. Sezer, W. Kern, H. Auner, 2003 .

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

X. Schiel, D. Buchheidt, F. Weissinger, 2017, Annals of Hematology.

S3-Leitlinie „Magenkarzinom” –

M. Ebert, H. Feußner, P. Malfertheiner, 2011 .

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

C. Bokemeyer, S. Hollerbach, R. Hofheinz, 2013, European journal of cancer.

Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005 .

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

J. Hasford, T. Brümmendorf, D. Hossfeld, 2016, Leukemia.

The valency state of absorbed iron appearing in the portal blood and ceruloplasmin substitution

R. Mahlberg, W. Rummel, P. Wollenberg, 2005, Biology of Metals.

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.

P. Malfertheiner, S. Kubicka, V. Heinemann, 2021, European journal of cancer.

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

M. Egger, V. Heinemann, J. Trojan, 2019, The Lancet.

Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction: A multicenter phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2007 .

Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer

V. Heinemann, B. Melichar, P. Janda, 2016, Gastric Cancer.

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial

F. Lordick, J. Trojan, R. Greil, 2023, ESMO Open.

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

A. Rosenwald, M. Ziepert, N. Schmitz, 2023, HemaSphere.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005, Blood.

P. Schirmacher, M. Egger, J. Trojan, 2016, The Lancet. Oncology.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

C. Rübe, M. Ziepert, N. Schmitz, 2014, Blood.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

R. Greil, H. Eich, R. Semrau, 2015, The Lancet.